Alger Small Cap Focus I US

Analyst Report
Morningstar's Take
|09/04/2024

by Tony Thomas
Alger Small Cap Focus remains a fairly attractive small-growth offering, but it comes with caveats.

Despite its name, the strategy seeks small companies (rather than small-cap companies) with operating revenues up to $500 million. Manager Amy Zhang brought this approach from her prior firm, Brown Capital Management, when she came to Alger in 2015. She also prefers companies with healthy finances, competitive strengths, and appealing long-term growth prospects (including the ability to double revenues in five years).

Much rides on Zhang. A high-energy, competitive investor, Zhang initially built a research team using Alger personnel, but over time most departed. Indeed, five have left since early 2020. Zhang picked up experienced external analysts to replace them, arguably improving the now seven-member team—though the current iteration needs to show it can stay together longer than prior versions. Even with the new help, Zhang is likely to remain the sole manager here for the foreseeable future.

The strategy’s track record isn’t as great as it once was. Companies with strong growth prospects—such as Zhang likes—attracted investors when interest rates were low but now face stiffer competition for capital. Share prices for many of Zhang’s best picks going into late 2021 suddenly went south, and results over Zhang’s nine-year tenure on the US mutual fund look relatively poor.

That’s not to say all is lost. Zhang used the selloff to trim long-term winners such as Veeva Systems to make room for smaller companies—often in the technology and healthcare sectors—like those that helped burnish her reputation early on. But one recent foray is odd. With the help of Alger colleague Sanjiv Talwar, Zhang jumped into biotechs in 2023. One early-stage company, Cabaletta Bio, was even a top-10 position in January 2024. That’s worrisome given Zhang’s long-standing preference for firms with existing lines of business. Speculative biotech stocks seem better relegated to this portfolio’s periphery (if they’re here at all), and investors should be wary if they’re increasingly treated otherwise.
 
Morningstar Medalist Rating™Intriguing but a bit puzzling.
To find out how Morningstar rates a fund click here.
Morningstar Pillars
PeopleAbove Average
ParentAverage
ProcessAbove Average
 
Morningstar Medalist RatingMorningstar assigns the Medalist Rating to funds that are qualitatively and quantitatively assessed through manager research and algorithmic processes. The assessment turns on three key “pillars” – People, Process, and Parent – that yield an estimate of how well a fund will perform before fees but after adjusting for risk.
Permissions/Reprints   E-mail Morningstar     
A fim de prover consistência para todos os relatórios fornecidos por diferentes Asset Managers, os data points calculados apresentados são gerados usando uma metodologia de cálculo proprietária da Morningstar, que pode ser conferida com mais detalhes em(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. Todos os direitos reservados.

Termos de Uso        Política Privacidade        Cookie Settings        Divulgações